No Data
Avilen: Amended temporary report
Emerging markets stock digest: AVILEN surged significantly, with Immune Biosciences hitting the limit up.
Stalemate. On the 11th, after the close of trading, the performance for the fiscal year ending August 2024 was announced, and it has been in a stalemate even after starting to rise.
Avilen announced the subsidiary integration of LangCore, an engineering group focused on AI development and rebound.
Stock rebounds. After the end of trading on the 11th, it was announced that LangCore, an engineering group specializing in AI development, would be acquired and consolidated as a subsidiary, which is being viewed favorably as positive news. The acquisition price is 0.4 billion yen. Through the subsidiary status of LangCore, it is expected to promptly create synergies such as further enhancing the company's AI technology capabilities, expanding development projects, and developing new AI saas. This will not only lead to short-term revenue growth for both companies but also is anticipated to drive business expansion in the medium to long term.
Shikigaku, the Institute of Immunobiology, and others [Emerging Markets Press Release]
<138A> Hikari Food Service downward revision, this term's operating profit outlook 20.2 billion yen ← 31.2 billion yen <2981> Lendix subsidiary established and new business initiated <4570> Immunobiology Research Institute acquires patent for 'Anti-HIV antibody and method of manufacturing' <4881> Roche initiates joint research with Fanpep on vaccine adjuvant for antibody-directed peptide <5591> Avilen engages in entrusted development of AI-related systems such as LangCo
Avilen: Extraordinary Report
OpenAI has raised 6.6 billion dollars.
OpenAI has reportedly secured $6.6 billion (approximately 960 billion yen) in its latest funding round. The company's valuation is estimated at $157 billion. It is reported that the company's efforts to build world-class technology in the field of artificial intelligence (AI) will be further strengthened.
No Data
No Data